COVID worsens asthma in children; booster after infection not as
beneficial vs Omicron
Send a link to a friend
[May 04, 2022] By
Nancy Lapid
(Reuters) - The following is a summary of
some recent studies on COVID-19. They include research that warrants
further study to corroborate the findings and that has yet to be
certified by peer review.
COVID-19 worsens asthma in children
Asthma in children may worsen after an infection with the coronavirus,
doctors warn.
They studied nearly 62,000 U.S. children with asthma who had PCR tests
for the virus in the first year of the pandemic, including more than
7,700 who tested positive. Infected children had significantly more
asthma visits, hospitalizations, emergency inhaler use, and steroid
treatments during the six months after their illness compared to
children who tested negative and to their own prior history, researchers
reported in the Journal of Allergy and Clinical Immunology: In Practice.
Children who tested negative for the virus "had improved asthma control
for the next six months, meaning fewer emergency department visits and
hospitalizations for asthma, and less asthma treatment," said Dr.
Christine Chou of Children's Health of Orange County, in California.
Results of earlier studies showing improvement in asthma control in the
early part of the pandemic were likely due to public health measures
like staying home and masking, which curbed exposure to asthma triggers,
she said. Despite the overall impression that children with asthma did
well during the first year of the pandemic, Chou added, the new study
shows "longer lasting harm of COVID on children's asthma control."
Booster after infection adds little extra benefit vs Omicron
Among people who were previously infected with the coronavirus, a third
dose of an mRNA vaccine from Pfizer/BioNTech or Moderna may not boost
their protection against the Omicron variant of the virus, according to
new data.
[to top of second column]
|
A child opens a testing swab at her desk so she can swab and test
herself for COVID-19 to prevent the spread of coronavirus disease
(COVID-19) in the classroom at South Boston Catholic Academy in
Boston, Massachusetts, U.S., January 28, 2021. REUTERS/Allison
Dinner
Researchers studied nearly 130,000 people tested for
COVID in Connecticut from November 2021 through January 2022,
including 10,676 with Omicron infections. Roughly 6% to 8% had been
infected with previous versions of the coronavirus, according to a
report posted on medRxiv ahead of peer review. Two doses of an mRNA
vaccine did help protect against Omicron among people with prior
infections, but "we did not detect an additional benefit of
receiving a third booster dose among this population," said Margaret
Lind of Yale University.
A separate study from Canada, also posted on medRxiv ahead of peer
review, similarly found that more than two vaccine doses "may be of
marginal incremental value" for protecting previously-infected
individuals against Omicron. The message, Lind said, "should be that
(1) people should get two doses of mRNA vaccine regardless of if
they have had a prior infection or not, that (2) people without
prior infections should get a booster dose and that (3) people with
prior infections should consider a booster dose, especially if they
are in a high risk group for life threatening complications, but
recognize that it may not provide significant additional protection
against infection above two doses."
(Reporting by Nancy Lapid; Editing by Bill Berkrot)
[© 2022 Thomson Reuters. All rights
reserved.]
This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|